How do you classify dietary supplements and protein powder under the HS code?

Why supplements are a classification puzzle

A protein powder sits at the intersection of three HS worlds. It is food, so chapters 1 through 24 beckon. It makes health claims, so chapter 30 pharmaceuticals whisper. It is a manufactured chemical mixture, so chapter 38 raises its hand. The General Rules of Interpretation resolve this through specificity and essential character, but reasonable people disagree on close calls, which is exactly why supplements generate so many classification disputes. The product's own marketing often argues against the importer's declared heading: a powder sold as muscle medicine looks less like a food preparation to CBP.

Presentation changes the analysis more than most brands expect. The same formulation in a 25-kilo bulk bag for further processing and in a 2-pound retail tub with a scoop are different classification exercises, because the HS cares how goods are put up. Retail packaging with dosage instructions points toward finished preparations; bulk drums point toward ingredients. Brands that import both configurations under one classification memo are building their audit exposure with every shipment.

The headings that usually win

For most finished protein powders and dietary supplements in retail packaging, heading 2106 (food preparations not elsewhere specified or included) is the workhorse. It is the basket provision for food products that do not fit more specific headings, and most supplement formats land here when the analysis is done honestly. The subheading then depends on composition: dairy-based proteins, sugar content, and specific ingredient profiles each have their own statistical suffixes with their own duty rates. Getting the six-digit heading right but the ten-digit suffix wrong still costs money on every entry.

The headings to rule out carefully are 3003 and 3004 (medicaments) and the chemical chapters. A supplement crosses into medicament territory when its presentation and claims make it therapeutic rather than nutritional, which is a facts-and-circumstances test CBP applies skeptically. Products with drug-like dosage instructions, disease claims, or pharmaceutical-style packaging invite the medicament analysis and its very different duty and regulatory consequences. When the marketing team writes disease claims and the trade team declares food preparations, the contradiction is visible to anyone who reads both, including CBP.

Ingredients that change everything

Specific ingredients can override the finished-product analysis. If the powder contains controlled botanicals, novel food ingredients, or substances regulated by partner agencies, the import compliance picture extends beyond CBP to FDA, and in some cases DEA or Fish and Wildlife. The HS classification and the agency jurisdiction are separate questions, but they interact: certain classifications flag the entry for agency review automatically. Brands that classify correctly but forget the agency requirements get the shipment held for reasons the classification memo never mentioned.

Country-specific ingredient rules add another layer for brands importing into multiple markets. An ingredient that is a routine food additive in the US may be restricted in the EU or require pre-market notification elsewhere. The classification that is settled domestically should be validated market by market rather than assumed, because the six harmonized digits are only the start and national implementations diverge. Build the ingredient review into product development, not into the shipping workflow, because reformulating after the first seizure is the most expensive way to learn.

Practical tips for getting it right

Classify the exact SKU you import, not the product family. Flavor variants with different sweetener systems, retail versus bulk configurations, and formula changes all deserve their own analysis. Keep a classification memo per SKU with the GRI reasoning written out, the competing headings considered and rejected, and the marketing materials attached. When CBP asks why the heading is right, the memo is the answer; without it, you are reconstructing reasoning under pressure.

When the answer is close, get a binding ruling. Supplements are exactly the kind of product where reasonable people disagree, and a ruling converts a judgment call into a defensible position. Include the full formulation, the packaging, the marketing claims, and your GRI analysis in the request. And revisit the classification when anything changes: a new functional ingredient, a shift from bulk to retail, or a marketing pivot toward therapeutic claims can all move the analysis. The brands with the fewest classification problems are not the ones that got it right once; they are the ones that recheck every time the product changes.